EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Trends and variation in the use of andexanet alfa for the reversal of direct oral anticoagulants in NHS trusts in England

Louis Fisher iD, Richard Buka iD, Rosalind Byrne iD, Stephen Black iD, Helen J Curtis iD, Christopher Wood iD, Andrew Brown iD, Sebastian Bacon iD, Richard Croker iD, Ben Goldacre iD, Brian MacKenna iD, Victoria Speed iD

British Journal of Clinical Pharmacology · 2025

DOI: 10.1002/bcp.70417 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Louis Fisher und 11 weiteren Autor:innen. Beteiligte Einrichtung: Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Factor Xa, Factor Xa Inhibitors, Practice Patterns, Physicians', Factor VIII. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR Biomedical Research Centre, Oxford, A Health Foundation Grant, A National Institute for Health Research (NIHR) School of Primary Care Research (SPCR) Grant, National Institute for Health Research (NIHR) under its Research for Patient Benefit (RfPB) Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Andexanet alfa was recommended by the National Institute for Health and Clinical Excellence (NICE) as an option in the management of life‐threatening gastrointestinal bleeding in patients taking apixaban or rivaroxaban in May 2021. A recent UK‐wide survey of local hospital protocols for the use of andexanet alfa suggested that practice across the United Kingdom is highly variable. In January 2025, NICE was unable to make a recommendation on the use of andexanet alfa for reversing anticoagulation in adults with intracranial haemorrhage. We set out to report trends and variation in the uptake of andexanet alfa across the NHS in England, using the new OpenPrescribing Hospitals platform.

Methods

To assess the uptake of andexanet alfa, we analysed pharmacy stock control data from NHS trusts in England using the openly available Secondary Care Medicines Dataset. Analysis was restricted to NHS trusts with 24‐h consultant‐led emergency care activity.

Results

Between May 2021 and June 2025, 19 608 vials of andexanet alfa were issued in NHS trusts in England. There was wide variation in the timing and speed of uptake across NHS trusts. Substantial variation was also observed between NHS Regions in England.

Conclusions

The use of andexanet alfa varies markedly between NHS regions and between NHS trusts in England. This study is the first analysis of adoption of a new treatment using the OpenPrescribing Hospitals platform, which is expected to provide a generalizable framework for similar analyses in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor XaFactor Xa InhibitorsPractice Patterns, Physicians'Factor VIIIIntracranial HemorrhagesHumansEnglandRecombinant ProteinsState MedicinePyridonesAdministration, OralRivaroxabanPyrazolesAnticoagulants

Stichwörter der Autor:innen

anticoagulant reversal agentsanticoagulantsantidotesthrombosis

Substanzen

Recombinant ProteinsPRT064445Factor XaFactor Xa InhibitorsapixabanPyridonesFactor VIIIRivaroxabanPyrazolesAnticoagulants

Autor:innen und Institutionen

  • Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
  • Department of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.
  • Haematology, King's Thrombosis Centre, King's College Hospital NHS Foundation Trust, London, UK.

ORCID-Profile: Louis Fisher, Richard Buka, Rosalind Byrne, Stephen Black, Helen J Curtis, Christopher Wood, Andrew Brown, Sebastian Bacon, Richard Croker, Ben Goldacre, Brian MacKenna, Victoria Speed

Förderung

  • NIHR Biomedical Research Centre, Oxford, A Health Foundation Grant
  • A National Institute for Health Research (NIHR) School of Primary Care Research (SPCR) Grant
  • National Institute for Health Research (NIHR) under its Research for Patient Benefit (RfPB) Programme
  • NHS England Primary Care and Medicines Analytics Unit

Zitieren

APA

Fisher, L., Buka, R., Byrne, R., Black, S., Curtis, H. J., Wood, C., Brown, A., Bacon, S., Croker, R., Goldacre, B., MacKenna, B., & Speed, V. (2025). Trends and variation in the use of andexanet alfa for the reversal of direct oral anticoagulants in NHS trusts in England. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70417

Vancouver

Fisher L, Buka R, Byrne R, Black S, Curtis HJ, Wood C, et al. Trends and variation in the use of andexanet alfa for the reversal of direct oral anticoagulants in NHS trusts in England. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70417

BibTeX
@article{Fisher2025,
  author = {Fisher, Louis and Buka, Richard and Byrne, Rosalind and Black, Stephen and Curtis, Helen J and Wood, Christopher and Brown, Andrew and Bacon, Sebastian and Croker, Richard and Goldacre, Ben and MacKenna, Brian and Speed, Victoria},
  title = {Trends and variation in the use of andexanet alfa for the reversal of direct oral anticoagulants in NHS trusts in England},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/bcp.70417}
}
Kostenlos starten →